394 related articles for article (PubMed ID: 32959678)
1. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
[TBL] [Abstract][Full Text] [Related]
3. The Impact and Statistical Analysis of a Multifaceted Anticoagulation Strategy in Children Supported on ECMO: Performance and Pitfalls.
Kessel AD; Kline M; Zinger M; McLaughlin D; Silver P; Sweberg TM
J Intensive Care Med; 2017 Jan; 32(1):59-67. PubMed ID: 26319579
[TBL] [Abstract][Full Text] [Related]
4. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
[TBL] [Abstract][Full Text] [Related]
5. The PiCT
Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
[TBL] [Abstract][Full Text] [Related]
6. Activated Partial Thromboplastin Time Versus Anti-Factor Xa Monitoring of Heparin Anticoagulation in Adult Venoarterial Extracorporeal Membrane Oxygenation Patients.
Kulig CE; Schomer KJ; Black HB; Dager WE
ASAIO J; 2021 Apr; 67(4):411-415. PubMed ID: 33769995
[TBL] [Abstract][Full Text] [Related]
7. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
Vandiver JW; Vondracek TG
Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
[TBL] [Abstract][Full Text] [Related]
8. Unfractionated heparin dosing in young infants: clinical outcomes in a cohort monitored with anti-factor Xa levels.
Schechter T; Finkelstein Y; Ali M; Kahr WH; Williams S; Chan AK; Deveber G; Brandão LR
J Thromb Haemost; 2012 Mar; 10(3):368-74. PubMed ID: 22244010
[TBL] [Abstract][Full Text] [Related]
9. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
[TBL] [Abstract][Full Text] [Related]
10. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
[TBL] [Abstract][Full Text] [Related]
11. Correlation Among Antifactor Xa, Activated Partial Thromboplastin Time, and Heparin Dose and Association with Pediatric Extracorporeal Membrane Oxygenation Complications.
McMichael ABV; Hornik CP; Hupp SR; Gordon SE; Ozment CP
ASAIO J; 2020 Mar; 66(3):307-313. PubMed ID: 30883406
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulation Monitoring Under ECMO Support: A Comparative Study Between the Activated Coagulation Time and the Anti-Xa Activity Assay.
Delmas C; Jacquemin A; Vardon-Bounes F; Georges B; Guerrero F; Hernandez N; Marcheix B; Seguin T; Minville V; Conil JM; Silva S
J Intensive Care Med; 2020 Jul; 35(7):679-686. PubMed ID: 29768983
[TBL] [Abstract][Full Text] [Related]
13. Activated Clotting Times Demonstrate Weak Correlation With Heparin Dosing in Adult Extracorporeal Membrane Oxygenation.
Hohlfelder B; Kelly D; Hoang M; Anger KE; Sylvester KW; Kaufman RM; Connors JM
Am J Ther; 2022 Jul; 29(4):e385-e393. PubMed ID: 31833874
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Anti-Xa and Activated Partial Thromboplastin Time Monitoring of Heparin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Support.
Arnouk S; Altshuler D; Lewis TC; Merchan C; Smith DE; Toy B; Zakhary B; Papadopoulos J
ASAIO J; 2020 Mar; 66(3):300-306. PubMed ID: 31045921
[TBL] [Abstract][Full Text] [Related]
15. Comparison of routine laboratory measures of heparin anticoagulation for neonates on extracorporeal membrane oxygenation.
Sulkowski JP; Preston TJ; Cooper JN; Duffy VL; Deans KJ; Chicoine LG; Minneci PC
J Extra Corpor Technol; 2014 Mar; 46(1):69-76. PubMed ID: 24779122
[TBL] [Abstract][Full Text] [Related]
16. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
[No Abstract] [Full Text] [Related]
17. Anti-Factor Xa-Based Anticoagulation during Extracorporeal Membrane Oxygenation: Potential Problems and Possible Solutions.
Ranucci M; Cotza M; Isgrò G; Carboni G; Ballotta A; Baryshnikova E;
Semin Thromb Hemost; 2020 Jun; 46(4):419-427. PubMed ID: 31563131
[TBL] [Abstract][Full Text] [Related]
18. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
Belk KW; Laposata M; Craver C
J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
[TBL] [Abstract][Full Text] [Related]
19. Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery.
Oladunjoye OO; Sleeper LA; Nair AG; Trenor CC; VanderPluym C; Kheir JN; Emani SM
J Thorac Cardiovasc Surg; 2018 Jul; 156(1):332-340.e1. PubMed ID: 29709361
[TBL] [Abstract][Full Text] [Related]
20. Conversion From Activated Clotting Time to Anti-Xa Heparin Activity Assay for Heparin Monitoring During Extracorporeal Membrane Oxygenation.
Figueroa Villalba CA; Brogan TV; McMullan DM; Yalon L; Jordan DI; Chandler WL
Crit Care Med; 2020 Dec; 48(12):e1179-e1184. PubMed ID: 33009103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
